IFNA1 and neoplasm: Immunotherapy aimed at increasing tumor heat may hold promise in those lacking immune activation or IFN signalling prior to chemotherapy or checkpoint inhibitors, supporting the notion of TME characterization pre-treatment to personalize therapy.